CG Oncology Reports Positive First Results from CORE‑008 Cohort CX Phase 2 Trial Evaluating Intravesical Combination Therapy in High-Risk BCG-Exposed and BCG-Unresponsive Patients
Go back to CG Oncology Reports Positive First Results from CORE‑008 Cohort CX Phase 2 Trial Evaluating Intravesical Combination Therapy in High-Risk BCG-Exposed and BCG-Unresponsive Patients| (NASDAQ: CGON) | Delayed: 71.12 +1.81 (2.61%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $69.31 | 52 Week High | $ | |||
| Open | $68.72 | 52 Week Low | $ | |||
| Day High | $72.99 | P/E | N/A | |||
| Day Low | $68.00 | EPS | $ | |||
| Volume | 1,036,491 | |||||
